Journal
NEUROPSYCHOLOGY REVIEW
Volume 17, Issue 2, Pages 179-188Publisher
SPRINGER
DOI: 10.1007/s11065-007-9023-0
Keywords
functional magnetic resonance imaging; drug development; anxiety; pharmacology; biomarkers
Categories
Funding
- NIMH NIH HHS [MH64122, MH075792, R01 MH075792-02, MH65413, R01 MH075792] Funding Source: Medline
Ask authors/readers for more resources
In this review, we survey the state of the field of functional magnetic resonance imaging (fMRI) as it relates to drug discovery and drug development. We highlight the advantages and limitations of fMRI for this purpose and suggest ways to improve the use of fMRI for developing new therapeutics, with emphasis on treatments for anxiety disorders. Fundamentally, pharmacological studies with standard psychiatric treatments using standardized behavioral probes during fMRI will need to be carried out to determine characteristic brain signatures that could be used to predict whether novel compounds are likely to have specific therapeutic effects.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available